Hongying W. Yang

No. 519 Kunzhou Road
Kunming, 650118, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 97 publications

Editorial: Advancing radioprotection: mechanisms, interventions, and therapeutic strategies.

Editorial: Advancing radioprotection: mechanisms, interventions, and therapeutic strategies.

Journal: Frontiers in pharmacology

Published: July 20, 2026

SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.

SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.

Journal: American journal of hematology

Published: April 21, 2026

Uncovering the Underlying Mechanism of Clotrimazole against Ovarian Cancer by Transcriptomics and Experimental Investigations.

Uncovering the Underlying Mechanism of Clotrimazole against Ovarian Cancer by Transcriptomics and Experimental Investigations.

Journal: Recent patents on anti-cancer drug discovery

Published: February 23, 2026

Clinical characteristics, treatment patterns, and prognosis in vulvar cancer and vaginal cancer: a national multicenter retrospective study in China.

Clinical characteristics, treatment patterns, and prognosis in vulvar cancer and vaginal cancer: a national multicenter retrospective study in China.

Journal: BMC public health

Published: January 28, 2026

Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior.

Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior.

Journal: Journal of gastrointestinal oncology

Published: September 30, 2025

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Journal: CA: a cancer journal for clinicians

Published: September 15, 2025

Serum creatinine, uric acid, and D-dimer levels as predictors of disease severity in hypertensive disorders of pregnancy.

Serum creatinine, uric acid, and D-dimer levels as predictors of disease severity in hypertensive disorders of pregnancy.

Journal: American journal of translational research

Published: August 13, 2025

A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC).

A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC).

Journal: Journal of ovarian research

Published: August 12, 2025

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.

Journal: Experimental hematology & oncology

Published: July 24, 2025

Author Correction: Tetrahydrobiopterin metabolism attenuates ROS generation and radiosensitivity through LDHA S-nitrosylation: novel insight into radiogenic lung injury.

Author Correction: Tetrahydrobiopterin metabolism attenuates ROS generation and radiosensitivity through LDHA S-nitrosylation: novel insight into radiogenic lung injury.

Journal: Experimental & molecular medicine

Published: July 14, 2025

Exosomes derived from ovarian cancer promote the progression of ovarian cancer through macrophage M2 polarization mediated by the THBS1/TGFBI signaling axis.

Exosomes derived from ovarian cancer promote the progression of ovarian cancer through macrophage M2 polarization mediated by the THBS1/TGFBI signaling axis.

Journal: Cellular immunology

Published: June 05, 2025

Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.

Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.

Journal: Nature communications

Published: May 19, 2025

Showing 1-12 of 97

Last Updated: 09/26/2026